A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.

Carlo Buonerba,Francesco Grillone,Sabrina Rossetti,Lorenzo Livi,Mario Scartozzi,Pierosandro Tagliaferri,Dario Bruzzese,Luca Scafuri,Vittorio Riccio,Ferdinando Costabile,Davide Bosso,Simona Iaccarino,Gaetano Facchini,Simone Carrano,Michela Izzo,Michele Caraglia,Sabino De Placido,Giuseppe Di Lorenzo

A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.

2019

Carlo Buonerba
Francesco Grillone
Sabrina Rossetti
Lorenzo Livi
Mario Scartozzi
Pierosandro Tagliaferri
Dario Bruzzese
Luca Scafuri
Vittorio Riccio
Ferdinando Costabile
Davide Bosso
Simona Iaccarino
Gaetano Facchini
Simone Carrano
Michela Izzo
Michele Caraglia
Sabino De Placido
Giuseppe Di Lorenzo

TPS345Background: In the TROPIC trial, cabazitaxel (CAB) plus daily prednisone (PDN) was associated with a significant advantage in OS and PFS in docetaxel (DOC)-pretreated patients (Pts). Whether ...

Keywords:

Cabazitaxel
Oncology
Prednisone
Castration
Phases of clinical research
Pathology
Prostate cancer
Internal medicine
Docetaxel
Medicine
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations